Overview

Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction

Status:
Recruiting

Trial end date:
2025-04-01

Target enrollment:
0

Participant gender:
All

Summary

Contemporary data are lacking regarding the management of left ventricular thrombus (LVT) developed after ST segment elevation myocardial infarction

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Jilin University

Treatments:

Rivaroxaban

Criteria

Inclusion Criteria:

Established ST segment elevation myocardial infarction within 7 days Left ventricular
thrombus (LVT) is detected by either cardiac magnetic resonance (CMR) or TTE.

Ongoing treatment with dual anti-platelet therapy according to ESC/AHA guidelines at the
time of randomization

Exclusion Criteria:

Clinically or hemodynamically unstable planed major surgeon such as CABG or Valve
replacement within next 12 months Concomitant condition that requires anti- coagulation
therapy, such as AF, DVT.

Any contraindication of anticoagulant therapy History of intracranial hemorrhage; Woman who
is currently pregnant, or breastfeeding serious impaired renal and liver functions life
expectancy less than 1 year can not provide consent